Pekabex S.A. (WSE:PBX), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in the past couple of months on the WSE. As a small cap stock, hardly covered by any analysts, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value. Is there still an opportunity here to buy? Let’s take a look at Pekabex’s outlook and value based on the most recent financial data to see if the opportunity still exists.
View our latest analysis for Pekabex
Is Pekabex still cheap?
The stock seems fairly valued at the moment according to my valuation model. It’s trading around 7.86% above my intrinsic value, which means if you buy Pekabex today, you’d be paying a relatively reasonable price for it. And if you believe the company’s true value is PLN14.56, there’s only an insignificant downside when the price falls to its real value. In addition to this, Pekabex has a low beta, which suggests its share price is less volatile than the wider market.
What kind of growth will Pekabex generate?
Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. In the upcoming year, Pekabex's earnings are expected to increase by 28%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.
What this means for you:
Are you a shareholder? PBX’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value?
Are you a potential investor? If you’ve been keeping an eye on PBX, now may not be the most optimal time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.
So while earnings quality is important, it's equally important to consider the risks facing Pekabex at this point in time. When we did our research, we found 5 warning signs for Pekabex (1 shouldn't be ignored!) that we believe deserve your full attention.
If you are no longer interested in Pekabex, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:PBX
Pekabex
A construction company, engages in the production and sale of prefabricated reinforced and pre-stressed concrete elements in Poland, Sweden, Denmark, Germany, Switzerland, Hungary, and internationally.
Mediocre balance sheet with questionable track record.